Novavax (NVAX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Novavax (NVAX) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Novavax's market cap?
Novavax (NVAX) has a market capitalization of approximately
How profitable is Novavax?
Novavax runs a net profit margin of -14.7%, a gross margin of 84.6%, and an operating margin of -11.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Novavax generate?
Novavax reported revenue of
Does Novavax pay a dividend?
Novavax does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Novavax financially healthy?
Novavax carries a debt-to-equity ratio of -2.04x and a current ratio of 2.48x, with a market beta of 2.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Novavax a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Novavax (NVAX) the key facts are: market cap
Track Novavax's full fundamentals live
Get Novavax's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.